| ［1］ |
世界肥胖联盟.2024年世界肥胖报告 ［EB/OL］.伦敦：世界肥胖联盟，2024.https：//data.worldobesity.org/publications/？cat=22
|
| ［2］ |
Peng W，Chen SQ，Chen XG，et al.Trends in major noncommunicable diseases and related risk factors in China 2002-2019：an analysis of nationally representative survey data ［J］.Lancet Reg Health West Pac，2024 ，43：100809.
|
| ［3］ |
心洁，壹图.《中国居民营养与慢性病状况报告（2020年）》国务院新闻办公室2020年12月23日新闻发布会（摘要） ［J］.中老年保健，2021，31（02）：14-21.
|
| ［4］ |
Garvey WT，Mechanick JI，Brett EM，et al.American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity ［J］.Endocr Pract，2016，22（7）：842-884.
|
| ［5］ |
Evert AB，Dennison M，Gardner CD，et al.Nutrition therapy for adults with diabetes or prediabetes：a consensus report ［J］.Diabetes Care，2019，42（5）：731-754.
|
| ［6］ |
Wing RR，Lang W，Wadden TA，et al.Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes ［J］.Diabetes Care，2011，34（7）：1481-1486.
|
| ［7］ |
Look AHEAD Research Group，Gregg EW，Jakicic JM，Blackburn G，et al.Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes：a post-hoc analysis of the look AHEAD randomised clinical trial ［J］.Lancet Diabetes Endocrinol，2016，4（11）：913-921.
|
| ［8］ |
Hall KD，Kahan S.Maintenance of lost weight and long-term management of obesity ［J］.Med Clin North Am，2018，102（1）：183-197.
|
| ［9］ |
Horn DB，Almandoz JP，Look M.What is clinically relevant weight loss for your patients and how can it be achieved？ A narrative review［J］.Postgrad Med，2022，134（4）：359-375.
|
| ［10］ |
Gloy VL，Briel M，Bhatt DL，et al.Bariatric surgery versus nonsurgical treatment for obesity：a systematic review and meta-analysis of randomised controlled trials ［J］.BMJ，2013，125：461.
|
| ［11］ |
中华医学会内分泌学会.肥胖患者的长期体重管理及药物临床应用指南（2024版） ［J］.中华内分泌代谢杂志，2024，40（7）：545-560.
|
| ［12］ |
Papamargaritis D，Le Roux CW.Do gut hormones contribute to weight loss and glycaemic outcomes after bariatric surgery？［J］.Nutrients，2021，13（3）：1-26.
|
| ［13］ |
Cegla J，Troke RC，Jones B，et al.Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake ［J］.Diabetes，2014，63（11）：3711-3720.
|
| ［14］ |
Salem V，Izzi-Engbeaya C，Coello C，et al.Glucagon increases energy expenditure independently of brown adipose tissue activation in humans ［J］.Diabetes Obes Metab，2016，18（1）：72-81.
|
| ［15］ |
Tan TM，Field BCT，McCullough KA，et al.Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyper-glycemia ［J］.Diabetes，2013，62（4）：1131-1138.
|
| ［16］ |
le Roux CW，Steen O，Lucas KJ，et al.Glucagon and GLP-1 receptor dual agonist survodutide for obesity：a randomised，double-blind，placebo-controlled，dose-finding phase 2 trial ［J］.Lancet Diabetes Endocrinol，2024，12（3）：162-173.
|
| ［17］ |
Blüher M，Rosenstock J，Hoefler J，et al.Dose-response effects on HbA1c and bodyweight reduction of survodutide，a dual glucagon/GLP-1 receptor agonist，compared with placebo and open-label semaglutide in people with type 2 diabetes：a randomised clinical trial［J］.Diabetologia，2024，67（3）：470-482.
|
| ［18］ |
Ji LN，Jiang HW，Cheng ZF，et al.A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity［J］.Nat Commun，2023，14（1）：8289.
|
| ［19］ |
Innovent.玛仕度肽（IBI362）高剂量9 mg在中国肥胖受试者中的II期临床研究达到24周主要终点 ［EB/OL］.苏州：Innovent，2023.https：//cn.innoventbio.com/#/news/485
|
| ［20］ |
Klein S，Nestor JJ，Harris MS，et al.Pemvidutide （ALT-801），a Balanced （1：1） GLP-1/Glucagon dual receptor agonist，induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity［J］.Diabetes，2022，71：334-OR.
|
| ［21］ |
Melson E，Ashraf U，Papamargaritis D，et al.What is the pipeline for future medications for obesity？ ［J］.Int J Obes （Lond），2024，Online ahead of print.
|
| ［22］ |
Alba M，Yee J，Frustaci ME，et al.Efficacy and safety of glucagonlike peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus：a randomized doseranging study ［J］.Clin Obes，2021，11（2）：e12432.
|
| ［23］ |
Lu SC，Chen M，Atangan L，et al.GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys ［J］.Cell Rep Med，2021，2（5）：100263.
|
| ［24］ |
Murielle M.Veniant，Shu-Chen Lu，Larissa Atangan，et al.A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings ［J］.Nat Merab，2024，6（2）：290-303.
|
| ［25］ |
Coskun T，Urva S，Roell WC，et al.LY3437943，a novel triple glucagon，GIP，and GLP-1 receptor agonist for glycemic control and weight loss：from discovery to clinical proof of concept ［J］.Cell Metab.2022，34（9）：1234-1247.
|
| ［26］ |
Jastreboff AM，Kaplan LM，Frías JP，et al.Triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial ［J］.N Engl J Med，2023，389（6）：514-526.
|
| ［27］ |
Rosenstock J，Frias J，Jastreboff AM，et al.Retatrutide，a GIP，GLP-1 and glucagon receptor agonist，for people with type 2 diabetes：a randomised，double-blind，placebo and active-controlled，parallelgroup，phase 2 trial conducted in the USA ［J］.Lancet，2023，402（10401）：529-544.
|
| ［28］ |
Knop FK，Aroda VR，do Vale RD，et al.OASIS 1 Investigators，Oral semaglutide 50 mg taken once per day in adults with overweight or obesity （OASIS 1）：a randomised，double-blind，placebo-controlled，phase 3 trial ［J］.Lancet，2023，402（10403）：705-719.
|
| ［29］ |
Aroda VR，Aberle J，Bardtrum L，et al.Efficacy and safety of oncedaily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes （PIONEER PLUS）：a multicentre，randomised，phase 3b trial ［J］.Lancet，2023，402（10403）：693-704.
|
| ［30］ |
Wilding J，Batterham RL，Calanna S，et al.Once-weekly semaglutide in adults with overweight or obesity ［J］.N Engl J Med，2021，384（11）：989-1002.
|
| ［31］ |
Davies M，Faerch L，J eppesen OK，et al.Semaglutide 2.4 mg once a week in adults with overweight or obesity，and type 2 diabetes（STEP2）：a randomised，double-blind，double-dummy，placebocontrolled，phase 3 trial ［J］.Lancet，2021，397（10278）：971-984.
|
| ［32］ |
Frias JP，Hsia S，Eyde S，et al.Efficacy and safety of oral orforglipron in patients with type 2 diabetes：a multicentre，randomised，doseresponse，phase 2 study ［J］.Lancet，2023，402（10400）：472-483.
|
| ［33］ |
Wharton S，Blevins T，Connery L，et al.Daily oral GLP-1 receptor agonist orforglipron for adults with obesity ［J］.N Engl J Med，2023，389（10）：877-888.
|
| ［34］ |
Griffith DA，Edmonds DJ，Fortin JP，et al.A small-molecule oral agonist of the human glucagon-like peptide-1 receptor ［J］.J Med Chem，2022，65（12）：8208-8226.
|
| ［35］ |
Saxena AR，Frias JP，Brown LS，et al.Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes：a randomized clinical trial ［J］.JAMA Netw Open，2023，6（5）：e2314493.
|
| ［36］ |
Lucacchini A.Amylin，Another important neuroendocrine hormone for the treatment of diabesity ［J］.Int J Mol Sci，2024，25（3）：1517.
|
| ［37］ |
Dehestani B，Stratford NRS，le Roux CW.Amylin as a future obesity treatment ［J］.J Obes Metab Syndr，2021，30（4）：320-325.
|
| ［38］ |
Frias JP，Deenadayalan S，Erichsen L，et al.Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes：a multicentre，randomised，double-blind，active-controlled，phase 2 trial ［J］.Lancet，2023，402（10403）：720-730.
|
| ［39］ |
Sanyal AJ，Bedossa P，Fraessdorf M，et al.A phase 2 randomized trial of survodutide in MASH and fibrosis ［J］.N Engl J Med，2024，391（4）：311-319.
|
| ［40］ |
Romero-Gómez M，Lawitz E，Shankar RR，et al.A phase IIa activecomparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease ［J］.J Hepatol，2023，79（4）：888-897.
|
| ［41］ |
Innovent.信达生物玛仕度肽在减重临床III期临床研究GLORY-1中肝脏脂肪含量降幅高达80.2% ［EB/OL］.苏州：Innovent，2024.https：//cn.innoventbio.com/#/news/564
|
| ［42］ |
Arun JS，Lee MK，Juan PF，et al.Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease：a randomized phase 2a trial ［J］.Nat Med，2024，30（7）：2037-2048.
|
| ［43］ |
Garito T，Roubenoff R，Hompesch M，et al.Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals ［J］.Diabetes Obes Metab，2018，20（1）：94-102.
|
| ［44］ |
Heymsfield SB，Coleman LA，Miller R，et al.Effect of bimagrumab vs.placebo on body fat mass among adults with type 2 diabetes and obesity：A phase 2 randomized clinical trial ［J］.JAMA Netw Open，2021，4（1）：e2033457.
|
| ［45］ |
Rooks D，Swan T，Goswami B，et al.Bimagrumab vs Optimized standard of care for treatment of sarcopenia in community-dwelling older adults：A randomized clinical trial ［J］.JAMA Netw Open，2020，3（10）：e2020836.
|
| ［46］ |
Rubino D，Abrahamsson N，Davies M，et al.Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity：The STEP 4 randomized clinical trial ［J］.JAMA，2021，325（14）：1414-1425.
|
| ［47］ |
Aronne LJ，Sattar N，Horn DB，et al.surmount-4 investigators，continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity：The SURMOUNT-4 randomized clinical trial ［J］.JAMA，2024，331（1）：38-48.
|
| ［48］ |
Lingvay I，Agarwal S.A revolution in obesity treatment ［J］.Nat Med，2023，29（10）：2406-2408.
|
| ［49］ |
Zhang L，Chen J，Zhang J，et al.Regional disparities in obesity among a heterogeneous population of Chinese children and adolescents ［J］.JAMA Netw Open，2021，4（10）：e2131040.
|
| ［50］ |
Joe Eun Son.Genetics，pharmacotherapy，and dietary interventions in childhood obesity ［J］.J Pharm Pharm Sci，2024，27：12861.
|
| ［51］ |
Lingvay I，Sumithran P，le Roux CW，et al.There is no magic bullet for obesity ［J］.Lancet Diabetes Endocrinol，2023，11（8）：541.
|
| ［52］ |
Verges B.Do anti-obesity medical treatment have a direct effect on adipose tissue？ ［J］.Ann Endocrinol （Paris），2024，85（3）：179-183.
|
| ［53］ |
Miras AD，Pérez-Pevida B，Aldhwayan M，et al.Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery （GRAVITAS）：a randomised，double-blind，placebo-controlled trial ［J］.Lancet Diabetes Endocrinol，2019，7（7）：549-559.
|